Investment Rating - The report does not provide a specific investment rating for the company [1] Core Viewpoints - The company has turned a profit after previously being in the red, with a net profit of $32.524 million in the first half of the year, compared to a loss of $8.952 million in the same period last year [1] - The company's revenue for the first half of the year was $2.07 billion, a year-on-year increase of 15.8%, with a gross margin of 20.4%, up 4.5 percentage points year-on-year [1] - The company's net profit margin is 1.6%, and the operating profit margin is 5.5% [1] - The company's management has provided guidance for full-year revenue growth in the high single digits, with gross margin expected to increase by 2.1 percentage points [1] - The company is advancing its "3+3" strategy, focusing on three key industries (EV, 5G AIoT, Audio) and three core technologies (copper to optical, wired to wireless, components to system products) [1] - The company plans to increase the revenue contribution from its "3+3" strategy to 30% in 2024 and 40% in 2025 [1] - The company's network infrastructure business is expected to benefit from NVIDIA's AI server and optical module development [1] - The company has secured orders from NVIDIA for compute trays, with a total value in the billions [1] - The company recently completed the acquisition of 70% of Huayun Optoelectronics to enhance its R&D capabilities in high-speed networks and optical markets [1] - The company is collaborating with MediaTek to develop CPO sockets, which will provide low-power solutions for AI servers [1] - The company's EV business is expected to grow by more than 50% for the full year, benefiting from synergies from acquisitions [1] - The company's Belkin brand business is expected to generate revenue of $700-800 million this year, with stable revenue and improving gross margins [1] Industry and Market Performance - The company operates in the TMT (Technology, Media, and Telecommunications) industry [1] - The company's stock price is currently at HKD 2.98, with a market capitalization of HKD 21.724 billion [1] - The company's 52-week high/low is HKD 3.95/HKD 0.88 [1] Strategic Developments - The company has been actively integrating resources through mergers and acquisitions, such as acquiring Belkin and Prettl SWH (renamed Voltaira) [1] - The company's network infrastructure business is expected to benefit from NVIDIA's AI server developments, with management raising guidance for network infrastructure revenue growth from mid-double digits to high double digits [1] - The company is focusing on expanding its presence in the EV market, particularly through its involvement in Tesla's supply chain and the production of CPD products [1] - The company is also working on developing 800G DR8 and SR8/DR8 optical products, with completion expected by the end of 2025 [1]

来源：公司资料，第一上海预测 来源：彭博 台积电（TSM） 更新报告 买入 2024 年 10 月 22 日 毛利率大超预期，积极筹备 N2、A16 制程投产 季度业绩摘要：24Q3 收入 7596.9 亿新台币，同比增长 39%，折 合 235 亿美元，高于上季度指引中值的 228 亿美元，也高于彭博 一致预期的 233 亿美元。其中晶圆收入 6700 亿新台币，7 纳米以 下的先进制程贡献52%的营收。Q3公司总成本3203.5亿新台币， 毛利率 57.8%，同比增长 3.5pct。经营利润 3607.7 亿新台币， 同比增长 58.2%。净利润 3250.8 亿新台币，同比增长 54.2%，折 合 100.9 亿美元，高于一致预期的 92.9 亿美元。摊薄后每 ADR 收 益同比增长 50.4%达 1.94 美元，高于一致预期的 1.80 美元。 AI 需求真实可持续，积极筹备 N2、A16 制程投产：本季度 3nm/5nm 制程分别贡献收入 20%/32%，同比增长 50%/3%。公司表 示当前 AI 需求是真实且可持续的，并且仍处于早期阶段。下一 代 N2、N2P、A16 制程需求均超预期，下游 A ...

Investment Rating - The report assigns a "Buy" rating to the company with a target price of HKD 2.35, indicating a potential upside of 54.6% from the current price of HKD 1.52 [1][31]. Core Insights - The company is a leading provider of supply chain financial technology solutions, leveraging technological innovation to drive growth. It was established in 2016 and became the first listed Chinese supply chain financial technology company on the Hong Kong Stock Exchange in 2021 [2][31]. - The company has a robust business model focused on supply chain financial technology solutions, which includes core enterprise cloud and financial institution cloud services. The company has achieved a cumulative service asset scale of over CNY 1.3 trillion, holding the largest market share in the industry [1][6]. - The company has diversified its customer base across various industries, with a significant increase in the number of core enterprise cloud clients and partners, reaching 726 and 1,750 respectively as of mid-2024 [7][31]. Summary by Sections Company Overview - The company focuses on providing supply chain financial technology solutions using advanced technologies such as AI, blockchain, and big data. It aims to optimize payment cycles and enhance the transparency and connectivity of the supply chain financial ecosystem [2][6]. Business Model - The main solutions offered include supply chain financial technology solutions and emerging solutions, with a focus on core enterprise cloud and financial institution cloud services. The company serves a wide range of core enterprises and financial institutions, facilitating efficient supply chain financing [6][8]. Financial Performance - The company reported a total asset processing volume of CNY 1,659 billion in the first half of 2024, representing a year-on-year growth of 17%. The revenue for the same period was CNY 400 million, showing a 4% increase compared to the previous year [19][31]. - The adjusted net profit for 2023 was negative due to changes in product structure and pricing, but it is expected to improve in the coming years as the gross margin recovers [21][31]. Market Position - The company holds a 20.9% market share in the domestic supply chain financial technology solutions sector, serving over 29,000 small and micro enterprises across China [25][31]. - The report highlights the increasing demand for integrated technology solutions in the supply chain finance sector, driven by the digital transformation of core enterprises and financial institutions [25][31]. Future Outlook - The company is expected to maintain a compound annual growth rate (CAGR) of 14% from 2024 to 2026 in asset processing volume, supported by a strong cash reserve of CNY 5.1 billion as of mid-2024 [24][31]. - The acquisition of a treasury management solution provider is anticipated to broaden the company's business scope and enhance its service offerings [29][31].

Investment Rating - The report assigns a "Buy" rating for the company, with a target price of HKD 39.09, indicating a potential upside of 26.10% from the current price of HKD 31.00 [1]. Core Insights - The company reported a positive performance in the first half of 2024, achieving revenue of RMB 11.25 billion, a year-on-year increase of 22.0%, and a net profit of RMB 5.4 billion, with a gross margin of 21.5% [1]. - The recovery in the smartphone market, along with the strong product mix in acoustics, optics, and precision structural components, is expected to drive growth in the second half of 2024 [1]. - The optical business is projected to turn profitable by the end of 2024, with revenue reaching RMB 2.21 billion, a year-on-year increase of 24.9% [1]. - The acoustic business continues to expand, with revenue of RMB 3.46 billion, a growth of 4.1% year-on-year, benefiting from high-end product upgrades [1]. Financial Summary - The company achieved total revenue of RMB 20.63 billion in 2022, with a projected increase to RMB 26.03 billion in 2024 and RMB 29.24 billion in 2025 [2]. - Gross profit for 2022 was RMB 3.78 billion, with a gross margin of 18.3%, expected to improve to 22.5% by 2024 [2]. - Net profit for 2022 was RMB 821.3 million, with projections of RMB 1.68 billion in 2024 and RMB 2.13 billion in 2025 [2]. - The company’s total assets were RMB 40.33 billion in 2022, projected to grow to RMB 48.52 billion by 2026 [2].

公司评论 第一上海研究部 research@firstshanghai.com.hk | --- | --- | --- | |---------------------|--------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Investment Rating - Buy rating maintained with a target price of HKD 17.39, implying a 32.7% upside from the current price [1][3] Core Views - Strong Q3 2024 performance with revenue of RMB 8.086 billion, up 26.64% YoY, and net profit attributable to shareholders of RMB 881 million, up 141.07% YoY [1] - Gold price surge driving profitability, with London spot gold reaching USD 2,648.8/oz, up 13.64% since June 2024 [1] - Incremental projects progressing well, including the full acquisition of Tietto and the development of the Haiyu Gold Mine, expected to contribute significantly to future growth [1] Financial Performance - Q3 2024 revenue reached RMB 3.458 billion, up 17.7% YoY, with net profit attributable to shareholders of RMB 328 million, up 192.86% YoY [1] - Forecasted net profit attributable to shareholders for 2024-2026: RMB 1.25 billion, RMB 1.98 billion, and RMB 2.7 billion, respectively [1] - EPS for 2024-2026 forecasted at RMB 0.37, RMB 0.58, and RMB 0.79, respectively [4] Gold Market and Company Positioning - Gold revenue accounted for 89% of total revenue and 99% of gross profit in H1 2024 [1] - Haiyu Gold Mine has a total gold resource of 562.37 tons and recoverable reserves of 212.21 tons, with an average grade of 4.42 g/t [1] - Tietto acquisition adds over 40 tons of gold reserves, with annual production expected to reach 5 tons [1] Valuation and Growth Prospects - Target price of HKD 17.39 based on 30x 2025 PE, reflecting strong growth potential from gold price trends and project developments [1] - Revenue growth forecasted at 53% in 2024, 23% in 2025, and 23% in 2026 [4] - Net profit growth forecasted at 82% in 2024, 57.8% in 2025, and 36.9% in 2026 [4] Financial Metrics - Gross margin improved to 45.2% in 2024E, 47.2% in 2025E, and 48.9% in 2026E [5] - Net margin expected to rise to 9.7% in 2024E, 12.4% in 2025E, and 13.9% in 2026E [5] - ROE forecasted at 6.4% in 2024E, 9.3% in 2025E, and 11.6% in 2026E [5]

石药集团（1093） 更新报告 集采致短期承压增速放缓，新产品陆续获批未来可期 买入 2024 年 10 月 4 日 高小迪 852-25321960 上半年收入增速不达预期：2024 年上半年公司营收 162.8 亿元（同比 +1.3%，下同），毛利 116.5 亿元（+3.7%），毛利率 71.6%（+1.7pts）。基 于财务报表所示股东应占溢利 20.2 亿元（+1.8%），归母净利率 18.5% （+0.1pts）。分板块看，成药板块录得收入 135.5 亿元（+4.8%），Q2 收入 环比出现明显萎缩；虽然维 C 原料产品价格缓慢回升，但需求回落，板块收 入上半年同比仍下降 5.4%，得 9.8 亿元；抗生素原料板块忧郁海外需求减 少，收入 8.7 亿元（-6.4%）；由于咖啡因产品价格下跌，功能食品板块收入 8.8 亿元（-25.2%）。 明复乐助力神经领域维持增长，恩必普院外市场开发空间广阔：成药板块 中，神经领域实现收入 52.36 亿元（+15.0%）。明复乐获批脑梗适应症，为 神经领域增长注入充足动力。相比心梗适应症，脑梗适应症能够更快速地放 量。恩必普 DoT 受医院医疗模式限制，尚未 ...

Investment Rating - The report assigns a "Buy" rating to the company with a target price of HKD 5.60, indicating a potential upside of 94.4% from the current price of HKD 2.88 [1]. Core Insights - The company has shown strong revenue growth driven by quality education services, with total revenue for FY24H1 reaching HKD 3.17 billion, a year-on-year increase of 68.1% [1]. - The adjusted net profit for FY24H1 was HKD 0.54 billion, reflecting a significant increase of 168.9% year-on-year [1]. - The company's contract liabilities have increased by 183.8% year-on-year, providing a solid foundation for future financial performance [1]. - The quality education segment has become the main growth engine, contributing HKD 1.23 billion in revenue, a growth of 31.9% year-on-year [1]. - The company has doubled its employee count to 1,785, supporting its rapid growth [1]. Financial Performance Overview - For FY24H1, the company reported a gross profit margin of 44.96%, an increase of 8.0 percentage points year-on-year [1]. - The operating profit margin improved significantly, with net profit margin rising to 23.4% from 17.2% year-on-year [1]. - The company expects revenue to reach HKD 10.91 billion in FY24, with a year-on-year growth of 123% [1]. - Forecasted net profit for FY24 is projected at HKD 185.2 million, with continued growth expected in subsequent years [2]. Business Strategy and Development - The company is actively optimizing its quality education courses and has successfully obtained non-profit school operation licenses in Guangzhou [1]. - New non-academic products have been launched, including "Fun Little Reporter" and "Literary Aesthetics," aligning with educational policies [1]. - The company is focused on compliance and transformation in response to regulatory changes, aiming to return to normal operational development [1]. Market Position and Outlook - The company is positioned as a leader in the education and training industry in South China, with expectations of continued market share growth [1]. - The report anticipates that the company will gradually return to a normal growth trajectory, supported by its strategic initiatives and market demand [1].

Investment Rating - The report assigns a "Buy" rating to the company with a target price of HKD 3.79, indicating a potential upside of 15.0% from the current price of HKD 3.30 [3][4]. Core Insights - The company is entering a harvest period for its innovative transformation, with a focus on oncology and a gradual improvement in product value [2]. - The risk from centralized procurement has been largely mitigated, and the company continues to see growth in its innovative products, achieving a revenue of HKD 158.7 billion in the first half of 2024, representing a year-on-year increase of 11.1% [2][3]. - The oncology segment generated revenue of HKD 53.6 billion, up 19.5%, accounting for 33.8% of total revenue [2]. Summary by Sections Financial Performance - The company reported a gross profit of HKD 130.3 billion, with a gross margin of 82.1%, reflecting an increase of 11.5% [2]. - Research and development expenses amounted to HKD 25.8 billion, a rise of 10.9%, with an expense ratio of 17% [2]. - The net profit attributable to shareholders reached HKD 30.2 billion, a significant increase of 139.7%, while the adjusted net profit was HKD 15.4 billion, up 14.0% [2]. Product Pipeline and Innovation - The company has accelerated its innovation efforts, focusing on four key areas: oncology, liver disease, respiratory, and surgical analgesia [3]. - In the first half of the year, the company received approval for three innovative drugs and one biosimilar, enhancing its product offerings [3]. - The oncology pipeline is particularly strong, with multiple drugs in clinical research and expected approvals that will drive future revenue growth [3]. Market Position and Valuation - The company has a market capitalization of HKD 620.1 billion and has issued 18.79 billion shares [4]. - The report uses a discounted cash flow (DCF) model for valuation, with a weighted average cost of capital (WACC) of 9.4% and a perpetual growth rate of 3% [3].

Investment Rating - The report assigns a "Buy" rating to the company with a target price of HKD 11.3, indicating a potential upside of 50.4% from the current price [2][3]. Core Insights - The company experienced a 6.1% quarter-on-quarter revenue growth in the first half of 2024, although year-on-year revenue decreased by 21.7% to RMB 3.61 billion [2]. - The sales of three national procurement products saw a significant decline of 49.2% year-on-year, while revenue from exclusive and innovative products reached RMB 2.41 billion, accounting for 56% of total revenue [2]. - The company is expected to see a gradual improvement in performance starting from the second half of 2024, driven by the commercialization of innovative products [2]. Financial Summary - Revenue for 2022 was RMB 9.15 billion, with a projected decline to RMB 8.01 billion in 2023 and further to RMB 7.60 billion in 2024, before recovering to RMB 8.75 billion in 2025 and RMB 9.83 billion in 2026 [4]. - The net profit attributable to shareholders is forecasted to decrease from RMB 3.26 billion in 2022 to RMB 2.40 billion in 2023, and further to RMB 1.75 billion in 2024, before increasing again in subsequent years [4]. - The company plans to launch 10-12 new drugs between 2025 and 2027, with a focus on innovative products that are expected to contribute significantly to revenue [2].